320 related articles for article (PubMed ID: 21175659)
21. Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors?
Busch MP
Transfus Clin Biol; 2004 Feb; 11(1):26-32. PubMed ID: 14980546
[TBL] [Abstract][Full Text] [Related]
22. Two HBV DNA+/HBsAg- blood donors identified by HBV NAT in Shenzhen, China.
Shang G; Yan Y; Yang B; Shao C; Wang F; Li Q; Seed CR
Transfus Apher Sci; 2009 Aug; 41(1):3-7. PubMed ID: 19487161
[TBL] [Abstract][Full Text] [Related]
23. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study.
Schreiber GB; Busch MP; Kleinman SH; Korelitz JJ
N Engl J Med; 1996 Jun; 334(26):1685-90. PubMed ID: 8637512
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of a multiplex human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus nucleic acid testing assay to detect viremic blood donors in northern Thailand.
Nantachit N; Thaikruea L; Thongsawat S; Leetrakool N; Fongsatikul L; Sompan P; Fong YL; Nichols D; Ziermann R; Ness P; Nelson KE
Transfusion; 2007 Oct; 47(10):1803-8. PubMed ID: 17880604
[TBL] [Abstract][Full Text] [Related]
25. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors.
Busch MP; Glynn SA; Stramer SL; Strong DM; Caglioti S; Wright DJ; Pappalardo B; Kleinman SH;
Transfusion; 2005 Feb; 45(2):254-64. PubMed ID: 15660836
[TBL] [Abstract][Full Text] [Related]
26. Predonation screening of blood donors with rapid tests: implementation and efficacy of a novel approach to blood safety in resource-poor settings.
Owusu-Ofori S; Temple J; Sarkodie F; Anokwa M; Candotti D; Allain JP
Transfusion; 2005 Feb; 45(2):133-40. PubMed ID: 15660820
[TBL] [Abstract][Full Text] [Related]
27. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program.
Satake M; Taira R; Yugi H; Hino S; Kanemitsu K; Ikeda H; Tadokoro K
Transfusion; 2007 Jul; 47(7):1197-205. PubMed ID: 17581154
[TBL] [Abstract][Full Text] [Related]
28. Tissue donation and virus safety: more nucleic acid amplification testing is needed.
Pruss A; Caspari G; Krüger DH; Blümel J; Nübling CM; Gürtler L; Gerlich WH
Transpl Infect Dis; 2010 Oct; 12(5):375-86. PubMed ID: 20412535
[TBL] [Abstract][Full Text] [Related]
29. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing.
Stramer SL; Glynn SA; Kleinman SH; Strong DM; Caglioti S; Wright DJ; Dodd RY; Busch MP;
N Engl J Med; 2004 Aug; 351(8):760-8. PubMed ID: 15317889
[TBL] [Abstract][Full Text] [Related]
30. Hepatitis B virus blood screening: unfinished agendas.
Comanor L; Holland P
Vox Sang; 2006 Jul; 91(1):1-12. PubMed ID: 16756595
[TBL] [Abstract][Full Text] [Related]
31. Effect of viral nucleic acid testing on contamination frequency of manufacturing plasma pools.
Nübling CM; Unkelbach U; Chudy M; Seitz R
Transfusion; 2008 May; 48(5):822-6. PubMed ID: 18208414
[TBL] [Abstract][Full Text] [Related]
32. Detection of HCV and HIV-1 antibody negative infections in Scottish and Northern Ireland blood donations by nucleic acid amplification testing.
Jarvis LM; Dow BC; Cleland A; Davidson F; Lycett C; Morris K; Webb B; Jordan A; Petrik J
Vox Sang; 2005 Oct; 89(3):128-34. PubMed ID: 16146504
[TBL] [Abstract][Full Text] [Related]
33. First report of human immunodeficiency virus transmission via an RNA-screened blood donation.
Delwart EL; Kalmin ND; Jones TS; Ladd DJ; Foley B; Tobler LH; Tsui RC; Busch MP
Vox Sang; 2004 Apr; 86(3):171-7. PubMed ID: 15078251
[TBL] [Abstract][Full Text] [Related]
34. Occult hepatitis B virus infection: implications in transfusion.
Allain JP
Vox Sang; 2004 Feb; 86(2):83-91. PubMed ID: 15023176
[TBL] [Abstract][Full Text] [Related]
35. Use of nucleic acid testing for blood donor screening of human immunodeficiency virus and hepatitis C virus in the Saudi population.
Akhter J; Roberts GT; Perry A; Gaucher JS; Howman PA
Saudi Med J; 2001 Dec; 22(12):1073-5. PubMed ID: 11802179
[TBL] [Abstract][Full Text] [Related]
36. [Transfusion-induced virus infections: how great is the risk?].
Sibrowski W; Penner M; Kühnl P
Infusionsther Transfusionsmed; 1993 Jun; 20 Suppl 2():4-9. PubMed ID: 8374287
[TBL] [Abstract][Full Text] [Related]
37. Transfusion-transmitted infectious diseases.
Allain JP; Stramer SL; Carneiro-Proietti AB; Martins ML; Lopes da Silva SN; Ribeiro M; Proietti FA; Reesink HW
Biologicals; 2009 Apr; 37(2):71-7. PubMed ID: 19231236
[TBL] [Abstract][Full Text] [Related]
38. [Risk of infection transmission by blood components].
Kubanek B; Cardoso M; Glück D; Koerner K
Infusionsther Transfusionsmed; 1993 Apr; 20(1-2):54-9. PubMed ID: 8504243
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of hepatitis B virus (HBV) DNA screening and characterization of acute and occult HBV infections among blood donors from Madrid, Spain.
González R; Torres P; Castro E; Barbolla L; Candotti D; Koppelman M; Zaaijer HL; Lelie N; Allain JP; Echevarría JM
Transfusion; 2010 Jan; 50(1):221-30. PubMed ID: 19682332
[TBL] [Abstract][Full Text] [Related]
40. Neopterin levels during the early phase of human immunodeficiency virus, hepatitis C virus, or hepatitis B virus infection.
Nübling CM; Chudy M; Volkers P; Löwer J
Transfusion; 2006 Nov; 46(11):1886-91. PubMed ID: 17076842
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
